ArticleThe Journal of clinical endocrinology and metabolism2007
Human visfatin expression: relationship to insulin sensitivity, intramyocellular lipids, and inflammation.
Article in The Journal of clinical endocrinology and metabolism, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT00108615. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Insulin Sensitizers in Subjects With Impaired Glucose Tolerance
Who cites it
73 citing papers in PubMed, 215 citations in OpenAlex.
- Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving.Translational psychiatry · 2015Trial
- Portal and systemic levels of visfatin in morbidly obese subjects undergoing bariatric surgery.Endocrine · 2013Trial
- Effect of weight reduction following bariatric surgery on serum visfatin and adiponectin levels in morbidly obese subjects.Obesity facts · 2013Trial
- Visfatin plasma concentrations in patients with hyperthyroidism and hypothyroidism before and after control of thyroid function.Journal of endocrinological investigation · 2009Trial
- Biomarkers of Cardiovascular Stress: A Historical Review.Journal of cardiovascular development and disease · 2026Review
- Multidimensional risk impact of obesity on breast cancer incidence, treatment, and prognosis.International journal of obesity (2005) · 2026Review
- Variants of Visceral Adipocytokine Genes in Obesity and Coronary Atherosclerosis: A Review.Current medicinal chemistry · 2026Review
- Distinct metabolic associations of subcutaneous and visceral adipocyte morphology in women with or without obesity.Scientific reports · 2025Article
- Role of Adipokines Chemerin, Visfatin, and Omentin in Obesity and Their Inflammatory and Metabolic Implications.Biomedicines · 2025Review
- Evaluation of Selected Serum Adipocytokines in Patients with Relapsing-Remitting Multiple Sclerosis Treated with Immunomodulatory Second-Line Drugs.International journal of molecular sciences · 2025Article
- Relationship of visfatin with obesity and osteoporosis in patients with inflammatory bowel disease: a narrative review.Frontiers in immunology · 2025Review
- Sleep Disorders in Connective Tissue Diseases-Coexisting Diseases or Disease Components?Journal of clinical medicine · 2024Review
- Nicotinamide mononucleotide induces lipolysis by regulating ATGL expression via the SIRT1-AMPK axis in adipocytes.Biochemistry and biophysics reports · 2023Article
- NAMPT-dependent NADProceedings of the National Academy of Sciences of the United States of America · 2023Article
- Evaluation of adipokines concentrations in plasma, peritoneal, and endometrioma fluids in women operated on for ovarian endometriosis.Frontiers in endocrinology · 2023Article
- Adipokines: Deciphering the cardiovascular signature of adipose tissue.Biochemical pharmacology · 2022Review
- Article
- Immunohistochemical identification and assessment of the location of leptin, visfatin and chemerin in the liver of men with different body mass index.BMC gastroenterology · 2022Article
- Comparative Transcriptome Analysis Provides Insight into Spatio-Temporal Expression Characteristics and Genetic Regulatory Network in Postnatal Developing Subcutaneous and Visceral Fat of Bama Pig.Frontiers in genetics · 2022Article
- Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus.International journal of molecular sciences · 2021Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 3 institutions in 1 country.
Funding
Abstract
contextVisfatin (VF) is a recently described adipokine preferentially secreted by visceral adipose tissue (VAT) with insulin mimetic properties.
objectiveThe aim of this study was to examine the association of VF with insulin sensitivity, intramyocellular lipids (IMCL), and inflammation in humans. DESIGN AND PATIENTS: VF mRNA was examined in paired samples of VAT and abdominal sc adipose tissue (SAT) obtained from subjects undergoing surgery. Plasma VF and VF mRNA was also examined in SAT and muscle tissue, obtained by biopsy from well-characterized subjects with normal or impaired glucose tolerance, with a wide range in body mass index (BMI) and insulin sensitivity (S(I)).
settingThe study was conducted at a University Hospital and General Clinical Research Center.
interventionS(I) was measured, and fat and muscle biopsies were performed. In impaired glucose tolerance subjects, these procedures were performed before and after treatment with pioglitazone or metformin.
main outcome measuresWe measured the relationship between VF and obesity, S(I), adipose tissue inflammation, IMCL, and response to insulin sensitizers.
resultsNo significant difference in VF mRNA was seen between SAT and VAT depots. VAT VF mRNA associated positively with BMI, whereas SAT VF mRNA decreased with BMI. SAT VF correlated positively with S(I), and the association of SAT VF mRNA with S(I) was independent of BMI. IMCL and markers of inflammation (adipose CD68 and plasma TNFalpha) were negatively associated with SAT VF. Impaired glucose tolerance subjects treated with pioglitazone showed no change in SAT VF mRNA despite a significant increase in S(I). Plasma VF and muscle VF mRNA did not correlate with BMI or S(I) or IMCL, and there was no change in muscle VF with either pioglitazone or metformin treatments.
conclusionSAT VF is highly expressed in lean, more insulin-sensitive subjects and is attenuated in subjects with high IMCL, low S(I), and high levels of inflammatory markers. VAT VF and SAT VF are regulated oppositely with BMI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.